• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: Does Pharmacogenomic Testing Reduce Drug-Gene Interactions in Patients with Major Depressive Disorder?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Only approximately 30% of patients with major depressive disorder (MDD) respond to the first treatment
  • Oslin et al. (JAMA, 2022) determined whether pharmacogenomic testing affects antidepressant medication selection and whether such testing leads to better clinical outcomes

METHODS:

  • Pragmatic, randomized clinical trial
    • The Precision Medicine in Mental Health Care (PRIME Care) Trial 
  • Participants
    • Patients at Department of Veterans Affairs medical centers with MDD who were initiating or switching treatment with a single antidepressant
    • Exclusions: Active substance use disorder | Mania | Psychosis | Concurrent treatment with a specified list of medications
  • Intervention
    • Clinicians given access to pharmacogenomic testing
    • Usual care with access to pharmacogenomic results revealed >24 weeks
  • Study design
    • Remission was measured with the Patient Health Questionnaire–9 (PHQ-9; remission was defined as PHQ-9 ≤ 5)
    • Remission was analyzed as a repeated measure across 24 weeks by blinded raters
  • Primary outcomes
    • The proportion of prescriptions with a predicted drug-gene interaction written in the 30 days after randomization
    • Remission of depressive symptoms

RESULTS:

  • Pharmacogenomic-guided group: 966 patients | Usual care group: 978 patients
    • Mean age: 48 years | 25% women | 79% completed 24-week assessment
  • Estimated risk of receiving antidepressants with
    • No drug-gene interactions
      • Pharmacogenomic-guided group: 59.3%
      • Usual care group: 25.7%
    • Moderate drug-gene interactions
      • Pharmacogenomic-guided group: 30.0%
      • Usual care group: 54.6%
    • Substantial drug-gene interactions
      • Pharmacogenomic-guided group: 10.7%
      • Usual care group: 19.7%
  • The pharmacogenomic-guided group was more likely to receive a medication with a lower potential drug-gene interaction
    • No drug-gene vs moderate/substantial interaction
      • OR 4.32 (95% CI, 3.47 to 5.39); P<0 .001
    • No/moderate vs substantial interaction
      • OR 2.08 (95% CI, 1.52 to 2.84); P=0.005
    • P<0.001 for overall comparison
  • Remission rates over 24 weeks were higher among patients whose care was guided by pharmacogenomic testing than those in usual care
    • OR 1.28 (95% CI, 1.05 to 1.57); P=0.02
    • Risk difference 2.8% (95% CI, 0.6 to 5.1)
  • Remission rates at week 24 weeks were not significantly different
    • Pharmacogenomic-guided group: 17.2%  
    • Usual care: 16.0%
    • Estimated risk difference 1.5% (95% CI, −2.4% to 5.3); P=0.45

CONCLUSION:

  • Compared to usual care, pharmacogenomic testing reduced that risk that patients with MDD would be prescribed an antidepressant that would have moderate or substantial drug-gene interactions
  • Symptom remission was higher in patients who underwent pharmacogenomic testing, but this effect was small and nonpersistent
  • The authors state

Overall, there were small positive effects on symptom remission over the 24 weeks with peak differences early in the trial and no significant difference in remission at 24 weeks

The negative consequences of pharmacogenomic testing are low and relate principally to cost

While the benefit on a population level may be limited, there may be value in the aggregate and to the individual patient

Learn More – Primary Sources:

Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

How Accurate is the Edinburgh Postnatal Depression Scale for Detecting Antepartum and Postpartum Depression?
Are Hormonal Contraceptives Associated with Increased Risk for Depression?
Should We Financially Incentivize Interventions to Prevent Postpartum Depression?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site